The EMT signaling pathways in endometrial carcinoma

[1]  X. Matías-Guiu,et al.  Endometrial carcinoma: molecular alterations involved in tumor development and progression , 2013, Oncogene.

[2]  R. López-López,et al.  ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas , 2012, Oncogene.

[3]  G. Scambia,et al.  The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma. , 2012, Gynecologic oncology.

[4]  H. Kim,et al.  Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. , 2012, Human pathology.

[5]  X. Matías-Guiu,et al.  Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease , 2012, Molecular and Cellular Endocrinology.

[6]  X. Matías-Guiu,et al.  ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells , 2012, International journal of cancer.

[7]  Margaret S. Ebert,et al.  Roles for MicroRNAs in Conferring Robustness to Biological Processes , 2012, Cell.

[8]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[9]  Ingrid Vandenput,et al.  Progesterone Inhibits Epithelial-to-Mesenchymal Transition in Endometrial Cancer , 2012, PloS one.

[10]  P. Dong,et al.  MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1 , 2011, Molecular Cancer.

[11]  J. Forteza,et al.  High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion , 2011, Molecular Cancer Therapeutics.

[12]  E. Howe,et al.  Targets of miR-200c mediate suppression of cell motility and anoikis resistance , 2011, Breast Cancer Research.

[13]  Libing Song,et al.  Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer , 2011, Molecular Cancer.

[14]  E. Oliva,et al.  Micro‐RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma , 2011, The Journal of pathology.

[15]  P. Altevogt,et al.  L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions , 2010, BMC Molecular Biology.

[16]  H. Ford,et al.  Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression , 2010, Journal of Mammary Gland Biology and Neoplasia.

[17]  S. Häusler,et al.  Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. , 2010, Anticancer research.

[18]  P. Altevogt,et al.  Up‐regulation of L1CAM is linked to loss of hormone receptors and E‐cadherin in aggressive subtypes of endometrial carcinomas , 2010, The Journal of pathology.

[19]  H. V. van Doorn,et al.  Progesterone Inhibition of Wnt/β-Catenin Signaling in Normal Endometrium and Endometrial Cancer , 2009, Clinical Cancer Research.

[20]  X. Matías-Guiu,et al.  Subtractive proteomic approach to the endometrial carcinoma invasion front. , 2009, Journal of proteome research.

[21]  R. López-López,et al.  Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. , 2009, Carcinogenesis.

[22]  C. Stewart,et al.  Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial–mesenchymal transition , 2009, Histopathology.

[23]  Xiu-fen Lei,et al.  TGFβ signaling supports survival and metastasis of endometrial cancer cells , 2009, Cancer management and research.

[24]  F. Portillo,et al.  Transcriptional regulation of cell polarity in EMT and cancer , 2008, Oncogene.

[25]  Domenico Coppola,et al.  MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA , 2008, Molecular and Cellular Biology.

[26]  M. Nieto,et al.  Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. , 2008, Trends in cell biology.

[27]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[28]  E. Hurt,et al.  Expression of the ZEB1 (δEF1) transcription factor in human: additional insights , 2008, Molecular and Cellular Biochemistry.

[29]  Meenakshi Singh,et al.  ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease , 2008, Modern Pathology.

[30]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[31]  L. Sui,et al.  Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. , 2008, Experimental oncology.

[32]  H. Höfler,et al.  The E-cadherin Repressor Snail Plays a Role in Tumor Progression of Endometrioid Adenocarcinomas , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[33]  F. Alameda,et al.  ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. , 2007, Cancer research.

[34]  A. García,et al.  Molecular determinants of invasion in endometrial cancer , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[35]  N. Park,et al.  Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. , 2006, Cancer letters.

[36]  V. Firlej,et al.  The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. , 2006, Biochimica et biophysica acta.

[37]  C. Creutzberg,et al.  COMBINED E-CADHERIN, ALPHA-CATENIN AND BETA- CATENIN EXPRESSION IS A FAVORABLE PROGNOSTIC FACTOR IN ENDOMETRIAL CARCINOMA , 2004, International Journal of Gynecologic Cancer.

[38]  S. Kyo,et al.  High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. , 2006, Human pathology.

[39]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[40]  F. Alameda,et al.  Up‐regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma , 2005, The Journal of pathology.

[41]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[42]  M. Nieto,et al.  The Snail genes as inducers of cell movement and survival: implications in development and cancer , 2005, Development.

[43]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[44]  C. Burger,et al.  Differences in Invasive Capacity of Endometrial Cancer Cell Lines Expressing Different Progesterone Receptor Isotypes: Possible Involvement of Cadherins , 2005, The Journal of the Society for Gynecologic Investigation: JSGI.

[45]  G. Berx,et al.  Unraveling signalling cascades for the Snail family of transcription factors. , 2005, Cellular signalling.

[46]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[47]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[48]  H. Kashima,et al.  Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. , 2004, Anticancer research.

[49]  A. Montag,et al.  Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial Cancer , 2004, Clinical Cancer Research.

[50]  J. Massagué,et al.  Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.

[51]  Jean Paul Thiery,et al.  Breast cancer progression with a Twist , 2004, Nature Medicine.

[52]  L. Akslen,et al.  Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[54]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[55]  C. Burger,et al.  Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Carlos S. Moreno,et al.  MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.

[57]  J. Herman,et al.  Abnormalities of E‐ and P‐cadherin and catenin (β‐, γ‐catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia , 2003 .

[58]  C. Burger,et al.  Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. , 2002, European journal of cancer.

[59]  M. Reiss,et al.  Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. , 2002, Cancer research.

[60]  K. Leslie,et al.  Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. , 2002, Cancer research.

[61]  M. Lohuizen,et al.  The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression , 2001, British Journal of Cancer.

[62]  O. Dietze,et al.  Co‐expression of tenascin‐C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins , 2001, The Journal of pathology.

[63]  E. Darai,et al.  Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma , 2001, Virchows Archiv.

[64]  R. Alvarez,et al.  Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  E. Furth,et al.  Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. , 1994, Gynecologic oncology.

[66]  G. Sutton,et al.  Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. , 1988, American journal of obstetrics and gynecology.

[67]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[68]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[69]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[70]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[71]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[72]  J. Herman,et al.  Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. , 2003, The Journal of pathology.

[73]  B. Graves,et al.  Specificity within the ets family of transcription factors. , 1998, Advances in cancer research.